Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Rohaan MW, et al. Among authors: kessels r. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. N Engl J Med. 2022. PMID: 36477031 Clinical Trial.
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
Vermunt MAC, Robbrecht DGJ, Devriese LA, Janssen JM, Thijssen B, Keessen M, van Eijk M, Kessels R, Eskens FALM, Beijnen JH, Mehra N, Bergman AM. Vermunt MAC, et al. Among authors: kessels r. Cancer Rep (Hoboken). 2021 Aug;4(4):e1367. doi: 10.1002/cnr2.1367. Epub 2021 Mar 12. Cancer Rep (Hoboken). 2021. PMID: 33709626 Free PMC article. Clinical Trial.
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.
Rohaan MW, Gomez-Eerland R, van den Berg JH, Geukes Foppen MH, van Zon M, Raud B, Jedema I, Scheij S, de Boer R, Bakker NAM, van den Broek D, Pronk LM, Grijpink-Ongering LG, Sari A, Kessels R, van den Haak M, Mallo HA, Karger M, van de Wiel BA, Zuur CL, Duinkerken CW, Lalezari F, van Thienen JV, Wilgenhof S, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. Rohaan MW, et al. Among authors: kessels r. Immunooncol Technol. 2022 Jun 18;15:100089. doi: 10.1016/j.iotech.2022.100089. eCollection 2022 Sep. Immunooncol Technol. 2022. PMID: 35865122 Free PMC article.
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW, Burgers FH, Terveer EM, van Leerdam ME, Korse CM, Kessels R, Flohil CC, Blank CU, Schumacher TN, van Dijk M, Henderickx JGE, Keller JJ, Verspaget HW, Kuijper EJ, Haanen JBAG. Borgers JSW, et al. Among authors: kessels r. BMC Cancer. 2022 Dec 30;22(1):1366. doi: 10.1186/s12885-022-10457-y. BMC Cancer. 2022. PMID: 36585700 Free PMC article.
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT, Rohaan MW, Jedema I, Kessels R, Stegeman W, Scheepmaker W, Nuijen B, Nijenhuis C, Lindenberg M, Borch TH, Monberg T, Donia M, Marie Svane I, van Harten W, Haanen J, Retel VP. Ten Ham RMT, et al. Among authors: kessels r. J Immunother Cancer. 2024 Mar 26;12(3):e008372. doi: 10.1136/jitc-2023-008372. J Immunother Cancer. 2024. PMID: 38531663 Free PMC article. Clinical Trial.
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
Vliek S, Hilbers FS, van Werkhoven E, Mandjes I, Kessels R, Kleiterp S, Lips EH, Mulder L, Kayembe MT, Loo CE, Russell NS, Vrancken Peeters MTFD, Holtkamp MJ, Schot M, Baars JW, Honkoop AH, Vulink AJE, Imholz ALT, Vrijaldenhoven S, van den Berkmortel FWPJ, Meerum Terwogt JM, Schrama JG, Kuijer P, Kroep JR, van der Padt-Pruijsten A, Wesseling J, Sonke GS, Gilhuijs KGA, Jager A, Nederlof P, Linn SC. Vliek S, et al. Among authors: kessels r. NPJ Breast Cancer. 2023 Sep 9;9(1):75. doi: 10.1038/s41523-023-00580-9. NPJ Breast Cancer. 2023. PMID: 37689749 Free PMC article.
Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma.
Al-Mamgani A, Kessels R, Verhoef CG, Navran A, Hamming-Vrieze O, Kaanders JHAM, Steenbakkers RJHM, Tans L, Hoebers F, Ong F, van Werkhoven E, Langendijk JA. Al-Mamgani A, et al. Among authors: kessels r. Radiother Oncol. 2020 Aug;149:181-188. doi: 10.1016/j.radonc.2020.05.020. Epub 2020 May 14. Radiother Oncol. 2020. PMID: 32417345 Clinical Trial.
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Among authors: kessels r. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.
499 results